• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Femasys Inc.

    3/31/26 5:11:50 PM ET
    $FEMY
    Medical/Dental Instruments
    Health Care
    Get the next $FEMY alert in real time by email
    S-8 1 ef20068660_s8.htm S-8
    As filed with the Securities and Exchange Commission on March 31, 2026

    Registration No. 333-

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549



    FORM S-8

    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933



    Femasys Inc.
    (Exact name of registrant as specified in its charter)

    Delaware
     
    11-3713499
    (State or other jurisdiction of incorporation or organization)
     
    (I.R.S. Employer Identification No.)

    3950 Johns Creek Court, Suite 100
    Suwanee, Georgia 30024
    (Address of principal executive offices) (Zip Code)



    FEMASYS INC. 2021 EQUITY INCENTIVE PLAN
    FEMASYS INC. EMPLOYEE STOCK PURCHASE PLAN
    (Full title of the Plans)



    Kathy Lee-Sepsick
    President and Chief Executive Officer
    3950 Johns Creek Court, Suite 100
    Suwanee, Georgia 30024
    (770) 500-3910
    (Name, address, including zip code, and telephone number, including area code, of agent for service)



    With a copy to:

    David S. Rosenthal, Esq.
    Anna Tomczyk, Esq.
    Dechert LLP
    1095 Avenue of Americas
    New York, New York 10036
    (212) 698-3616



    Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    Large accelerated filer ☐
    Accelerated filer ☐
    Non-accelerated filer ☒
    Smaller reporting company ☒
     
    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☒



    REGISTRATION OF ADDITIONAL SHARES
    PURSUANT TO GENERAL INSTRUCTION E

    Pursuant to General Instruction E of Form S-8, the Registrant is filing this Registration Statement with the Securities and Exchange Commission (the “Commission”) to register (i) 5,384,100 additional shares of common stock under the Femasys Inc. 2021 Equity Incentive Plan (the “2021 Plan”), consisting of (a) 2,384,100 shares of common stock added on January 1, 2026 pursuant to the provision of the 2021 Plan providing for an annual automatic increase in the number of shares reserved for issuance and (b) 3,000,000 shares of common stock that were approved by the Registrant’s stockholders at the Registrant’s annual meeting of stockholders held on June 25, 2025 to increase the number of shares authorized for issuance under the 2021 Plan, and (ii) 596,025 additional shares of common stock under the Femasys Inc. Employee Stock Purchase Plan (the “ESPP”) that were added on January 1, 2026 pursuant to the provision of the ESPP providing for an annual automatic increase in the number of shares reserved for issuance. This Registration Statement hereby incorporates by reference the contents of the Registrant’s registration statements on Form S-8 filed with the Commission on June 22, 2021 (Registration No. 333-257284), March 24, 2022 (Registration No. 333-263833), April 5, 2023 (Registration No. 333-271139), April 5, 2024 (Registration No. 333-278541) and March 27, 2025 (Registration No. 333-286155).

    Item 8.
    Exhibits.

    EXHIBIT INDEX

    Exhibit
    Number
     
    Exhibit Description
         
    5.1*
     
    Opinion of Dechert LLP.
         
    23.1*
     
    Consent of Dechert LLP (included in Exhibit 5.1).
         
    23.2*
     
    Consent of KPMG LLP.
         
    24.1*
     
    Power of Attorney (included on signature page).
         
    99.1
     
    Femasys Inc. 2021 Equity Incentive Plan, and forms of agreements thereunder (Incorporated by reference to Exhibit 10.3 of the Registrant’s Registration Statement on Form S-1 (File No. 333-256156) filed May 14, 2021).
         
    99.2
     
    Femasys Inc. Employee Stock Purchase Plan (Incorporated by reference to Exhibit 10.4 of the Registrant’s Registration Statement on Form S-1 (File No. 333-256156) filed May 14, 2021).
         
    107*
     
    Filing Fee Table

    *
    Filed herewith.


    SIGNATURES

    Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Suwanee, State of Georgia on March 31, 2026.

    FEMASYS INC.
     
    By:
    /s/ Kathy Lee-Sepsick
     
    Kathy Lee-Sepsick
     
    Chief Executive Officer and President


    POWER OF ATTORNEY

    KNOW ALL BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Kathy Lee-Sepsick and Dov Elefant, and each of them, as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to sign any Registration Statement for the same offering covered by this Registration Statement that is to be effective upon filing pursuant to Rule 462(b) promulgated under the Securities Act, and all post-effective amendments thereto, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof. Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities held and on the dates indicated.

    Signature
     
    Title
     
    Date
     
     
     
     
     
    /s/ Kathy Lee-Sepsick
     
    President, Chief Executive Officer and Director (principal executive officer)
     
    March 31, 2026
    Kathy Lee-Sepsick
     
     
     
     
     
     
     
     
     
    /s/ Dov Elefant
     
    Chief Financial Officer (principal financial and accounting officer)
     
    March 31, 2026
    Dov Elefant
     
     
     
     
     
     
     
     
     
    /s/ Charles Larsen
     
    Chair of the Board of Directors
     
    March 31, 2026
    Charles Larsen
     
     
     
     
     
     
     
     
     
    /s/ Alistair Milnes
     
    Director
     
    March 31, 2026
    Alistair Milnes
     
     
     
     
     
     
     
     
     
    /s/ Kenneth D. Eichenbaum
     
    Director
     
    March 31, 2026
    Kenneth D. Eichenbaum
     
     
     
     
     
     
     
     
     
    /s/ Edward Uzialko, Jr.
     
    Director
     
    March 31, 2026
    Edward Uzialko, Jr.
     
     
     
     



    Get the next $FEMY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FEMY

    DatePrice TargetRatingAnalyst
    11/20/2025$6.50Buy
    Laidlaw
    7/13/2021$18.00Buy
    JonesTrading
    7/13/2021$25.00Buy
    Chardan Capital
    More analyst ratings

    $FEMY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Lee-Sepsick Kathy

    4 - FEMASYS INC (0001339005) (Issuer)

    3/27/26 5:00:26 PM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Elefant Dov

    4 - FEMASYS INC (0001339005) (Issuer)

    3/27/26 5:00:26 PM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Larsen Charles

    4 - FEMASYS INC (0001339005) (Issuer)

    3/27/26 5:00:25 PM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    $FEMY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Femasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate Update

    ATLANTA, March 31, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced its financial results for the year ended December 31, 2025 and provides a corporate update. Corporate Highlights from 4Q 2025 to date Initiated patient enrollment in the FINALE pivotal clinical trial evaluating FemBloc, advancing toward U.S. approval.Appointed Kenneth D. Eichenbaum, M.D., M.S.E., to the Board of Directors, strengthening leadership and strategic oversight.FemBloc permanent birth control system achieved certification under the Medical Device Single Au

    3/31/26 4:05:00 PM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    Femasys Appoints Dr. Kenneth D. Eichenbaum to Board of Directors

    ATLANTA, March 18, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced today the appointment of Kenneth D. Eichenbaum, M.D., M.S.E., to its Board of Directors. Dr. Eichenbaum is a board-certified anesthesiologist with clinical affiliations at Corewell Health William Beaumont University Hospital and Trinity Health Oakland Hospital, bringing deep clinical expertise and strategic insight developed through more than 20 years of evaluating biotechnology and medical device companies and advising investment firms. He completed a fel

    3/18/26 9:00:00 AM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    Femasys Advances FemBloc Toward U.S. Approval with Initiation of Pivotal Trial Enrollment

    -- Enrollment begins in the FDA-authorized FINALE pivotal trial evaluating FemBloc, a first-of-its-kind non-surgical permanent birth control, following positive clinical data -- ATLANTA, March 10, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced today the initiation of patient enrollment in the FINALE pivotal clinical trial evaluating FemBloc. This milestone follows U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) approval to advance the study based on positive clinical data generated in its

    3/10/26 9:00:00 AM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    $FEMY
    SEC Filings

    View All

    SEC Form S-8 filed by Femasys Inc.

    S-8 - FEMASYS INC (0001339005) (Filer)

    3/31/26 5:11:50 PM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    SEC Form 10-K filed by Femasys Inc.

    10-K - FEMASYS INC (0001339005) (Filer)

    3/31/26 5:04:20 PM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    Femasys Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - FEMASYS INC (0001339005) (Filer)

    3/31/26 4:18:51 PM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    $FEMY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Laidlaw initiated coverage on Femasys with a new price target

    Laidlaw initiated coverage of Femasys with a rating of Buy and set a new price target of $6.50

    11/20/25 8:06:38 AM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    JonesTrading initiated coverage on Femasys with a new price target

    JonesTrading initiated coverage of Femasys with a rating of Buy and set a new price target of $18.00

    7/13/21 11:41:28 AM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    Chardan Capital initiated coverage on Femasys with a new price target

    Chardan Capital initiated coverage of Femasys with a rating of Buy and set a new price target of $25.00

    7/13/21 8:04:59 AM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    $FEMY
    Leadership Updates

    Live Leadership Updates

    View All

    Femasys Appoints Dr. Kenneth D. Eichenbaum to Board of Directors

    ATLANTA, March 18, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced today the appointment of Kenneth D. Eichenbaum, M.D., M.S.E., to its Board of Directors. Dr. Eichenbaum is a board-certified anesthesiologist with clinical affiliations at Corewell Health William Beaumont University Hospital and Trinity Health Oakland Hospital, bringing deep clinical expertise and strategic insight developed through more than 20 years of evaluating biotechnology and medical device companies and advising investment firms. He completed a fel

    3/18/26 9:00:00 AM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    Femasys Closes $8 Million in Financing to Accelerate Commercialization of Fertility and Birth Control Portfolios

    --Existing investors, including Femasys' largest shareholders, reaffirm confidence in Femasys' strategy for growth and impact in women's health-- ATLANTA, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced today the closing of $8 million in financing. This funding will provide critical resources to accelerate commercialization efforts and strengthen the company's ability to address significant unmet needs in women's reproductive health. To underscore this momentum, Femasys' largest shareholder, Jorey Chernett also provided co

    9/2/25 9:00:00 AM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    Femasys Names New Chief Commercial Officer to Drive Execution and Global Growth

    --New CCO to Lead U.S. Commercialization of Fertility Products, Including FemaSeed®, and Expand Strategic Global Partnerships Across Full Portfolio-- ATLANTA, June 17, 2025 (GLOBE NEWSWIRE) -- Femasys, Inc. (NASDAQ:FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, today announced the appointment of Kelley Nicholas as Chief Commercial Officer (CCO). Ms. Nicholas will be responsible for leading the execution and optimization of Femasys' commercial strategy to drive revenue growth across its entire portfolio, with a particular focus on e

    6/17/25 9:00:00 AM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    $FEMY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Femasys Inc.

    SC 13D - FEMASYS INC (0001339005) (Subject)

    11/22/23 4:00:15 PM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    $FEMY
    Financials

    Live finance-specific insights

    View All

    Femasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate Update

    ATLANTA, March 31, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced its financial results for the year ended December 31, 2025 and provides a corporate update. Corporate Highlights from 4Q 2025 to date Initiated patient enrollment in the FINALE pivotal clinical trial evaluating FemBloc, advancing toward U.S. approval.Appointed Kenneth D. Eichenbaum, M.D., M.S.E., to the Board of Directors, strengthening leadership and strategic oversight.FemBloc permanent birth control system achieved certification under the Medical Device Single Au

    3/31/26 4:05:00 PM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    Femasys Announces Financial Results for Quarter Ended March 31, 2025, and Provides Corporate Update

    -- Company delivers on mission to transform women's health with innovative solutions, including FemaSeed® for first-line infertility treatment and FemBloc® non-surgical permanent birth control (full system approval pending in Europe) -- ATLANTA, May 08, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, announces financial results for the quarter ended March 31, 2025 and provides a corporate update. Corporate Highlights from 1Q 2025 to date Announced FemBloc permanent birth control delivery syste

    5/8/25 5:01:00 PM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update

    -- Company expands commercial product offering with FemBloc® permanent birth control (delivery system) approval in Europe and signed partnerships for distribution in Spain -- ATLANTA, March 27, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, announces financial results for the year ended December 31, 2024 and provides a corporate update. Corporate Highlights from 4Q 2024 to date Announced FemBloc® permanent birth control (delivery system) approval in Europe; FemBloc blended polymer component s

    3/27/25 9:00:00 AM ET
    $FEMY
    Medical/Dental Instruments
    Health Care